Abstract
Helicobacter pylori (H. pylori) represents one of the most widespread bacterial infections globally. Infection causes chronic gastritis and increases the risk of peptic ulcer disease, gastric adenocarcinoma, and mucosa-associated lymphoid tissue lymphoma. The pioneering discovery of H. pylori by Marshall and Warren in the early 1980s has initiated fervent research into H. pylori as a pathogen ever since. This chapter aims to provide an overview of our understanding of H. pylori infection and its management, with a focus on current options for diagnosis, the challenges associated with H. pylori eradication, and the need for alternative therapeutic strategies based on furthering our understanding of host: H. pylori interactions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Salama NR, Hartung ML, Muller A (2013) Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nat Rev Microbiol 11:385–399
Fallone CA, Chiba N, van Zanten SV et al (2016) The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 151:51–69
McColl KE (2010) Clinical practice. Helicobacter pylori infection. N Engl J Med 362:1597–1604
Plummer M, Franceschi S, Vignat J et al (2015) Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer 136:487–490
Marshall B, Warren JR (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 323:1311–1315
Marshall BJ, Armstrong JA, McGechie DB et al (1985) Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust 142:436–439
Smith SM (2014) Role of Toll-like receptors in Helicobacter pylori infection and immunity. World J Gastrointest Pathophysiol 5:133–146
Pachathundikandi SK, Müller A, Backert S (2016) Inflammasome activation by Helicobacter pylori and its implications for persistence and immunity. In: Backert S (ed) Inflammasome signaling and bacterial infections. Springer, Cham, Switzerland, pp 117–131
Matos JI, de Sousa HA, Marcos-Pinto R et al (2013) Helicobacter pylori CagA and VacA genotypes and gastric phenotype: a meta-analysis. Eur J Gastroenterol Hepatol 25:1431–1441
Salimzadeh L, Bagheri N, Zamanzad B et al (2015) Frequency of virulence factors in Helicobacter pylori-infected patients with gastritis. Microb Pathogen 80:67–72
Razavi A, Bagheri N, Azadegan-Dehkordi F et al (2015) Comparative immune response in children and adults with H. pylori infection. J. Immunol Res 2015:315957
Eusebi LH, Zagari RM, Bazzoli F (2014) Epidemiology of Helicobacter pylori infection. Helicobacter 19:1–5
Bui D, Brown HE, Harris RB et al (2016) Serologic evidence for fecal–oral transmission of Helicobacter pylori. Am J Trop Med Hyg 94:82–88
Leja M, Axon A, Brenner H (2016) Epidemiology of Helicobacter pylori infection. Helicobacter 21:3–7
Aziz RK, Khalifa MM, Sharaf RR (2015) Contaminated water as a source of Helicobacter pylori infection: a review. J Adv Res 6:539–547
Chakrani Z, Robinson K, Taye B (2018) Association between ABO blood groups and Helicobacter pylori infection: a meta-analysis. Sci Rep 8:17,604
Hooi JKY, Lai WY, Ng WK et al (2017) Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 153:420–429
van Blankenstein M, van Vuuren AJ, Looman CW et al (2013) The prevalence of Helicobacter pylori infection in the Netherlands. Scand J Gastroenterol 48:794–800
Bastos J, Peleteiro B, Barros R et al (2013) Sociodemographic determinants of prevalence and incidence of Helicobacter pylori infection in Portuguese adults. Helicobacter 18:413–422
Lim SH, Kwon J-W, Kim N et al (2013) Prevalence and risk factors of Helicobacter pylori infection in Korea: nationwide multicenter study over 13 years. BMC Gastroenterol 13:104
Zhu Y, Zhou X, Wu J et al (2014) Risk factors and prevalence of Helicobacter pylori infection in persistent high incidence area of gastric carcinoma in Yangzhong city. Gastroenterol Res Pract 2014:481365
Pan K-F, Zhang L, Gerhard M et al (2015) A large randomized controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. Gut 65:9–18
Mathewos B, Moges B, Dagnew M (2013) Seroprevalence and trend of Helicobacter pylori infection in Gondar University Hospital among dyspeptic patients, Gondar, North West Ethiopia. BMC Res Notes 6:346
Alvarado-Esquivel C (2013) Seroepidemiology of Helicobacter pylori infection in pregnant women in rural Durango, Mexico. Int J Biomed Sci 9:224
Brennan DE, Omorogbe J, Hussey M et al (2016) Molecular detection of Helicobacter pylori antibiotic resistance in stool vs biopsy samples. World J Gastroenterol 22:9214–9221
Wang Y-K, Kuo F-C, Liu C-J et al (2015) Diagnosis of Helicobacter pylori infection: Current options and developments. World J Gastroenterol 21:11221
Malfertheiner P, Megraud F, O’Morain CA et al (2017) Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 66:6–30
Malfertheiner P, Megraud F, O’Morain C et al (1997) Current European concepts in the management of Helicobacter pylori infection-the Maastricht Consensus Report. Eur J Gastroenterol Hepatol 9(1):1–2
Smith SM, Haider RB, O’Connor H et al (2014) Practical treatment of Helicobacter pylori: a balanced view in changing times. Eur J Gastroenterol Hepatol 26:819–825
Chey WD, Leontiadis GI, Howden CW et al (2017) ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 112:212–239
Thung I, Aramin H, Vavinskaya V et al (2016) The global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 43:514–533
Megraud F, Coenen S, Versporten A et al (2013) Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 62:34–42
Smith SM (2015) An update on the treatment of Helicobacter pylori infection. EMJ Gastroenterol 4:101–107
Smith SM, O’Morain C, McNamara D (2019) Helicobacter pylori resistance to current therapies. Curr Opin Gastroenterol 35:6–13
Zhang X, Arnold IC, Muller A (2020) Mechanisms of persistence, innate immune activation and immunomodulation by the gastric pathogen Helicobacter pylori. Curr Opin Microbiol 54:1–10
Whitney AE, Emory TS, Marty AM et al (2000) Increased macrophage infiltration of gastric mucosa in Helicobacter pylori-infected children. Dig Dis Sci 45:1337–1342
Suzuki T, Kato K, Ohara S et al (2002) Localization of antigen-presenting cells in Helicobacter pylori-infected gastric mucosa. Pathol Int 52:265–271
Cherdantseva LA, Potapova OV, Sharkova TV et al (2014) Association of Helicobacter pylori and iNOS production by macrophages and lymphocytes in the gastric mucosa in chronic gastritis. J Immunol Res 2014:762514
Xia HH, Lam SK, Huang XR et al (2004) Helicobacter pylori infection is associated with increased expression of macrophage migratory inhibitory factor-by epithelial cells, T cells, and macrophages-in gastric mucosa. J Infect Dis 190:293–302
Smith SM, Moran AP, Duggan SP et al (2011) Tribbles 3: a novel regulator of TLR2-mediated signaling in response to Helicobacter pylori lipopolysaccharide. J Immunol 186:2462–2471
Wen S, Felley CP, Bouzourene H et al (2004) Inflammatory gene profiles in gastric mucosa during Helicobacter pylori infection in humans. J Immunol 172:2595–2606
Marcos NT, Magalhaes A, Ferreira B et al (2008) Helicobacter pylori induces beta3GnT5 in human gastric cell lines, modulating expression of the SabA ligand sialyl-Lewis x. J Clin Invest 118:2325–2336
Kusugami K, Ando T, Ohsuga M et al (1997) Mucosal chemokine activity in Helicobacter pylori infection. J Clin Gastroenterol 25(Suppl 1):S203–S210
Yamaoka Y, Kita M, Kodama T et al (1998) Chemokines in the gastric mucosa in Helicobacter pylori infection. Gut 42:609–617
Suzuki H, Mori M, Sakaguchi AA et al (1998) Enhanced levels of C-X-C chemokine, human GROalpha, in Helicobacter pylori-associated gastric disease. J Gastroenterol Hepatol 13:516–520
Wu YY, Tsai HF, Lin WC et al (2007) Upregulation of CCL20 and recruitment of CCR6+ gastric infiltrating lymphocytes in Helicobacter pylori gastritis. Infect Immun 75:4357–4363
Tran LS, Chonwerawong M, Ferrero RL (2017) Regulation and functions of inflammasome-mediated cytokines in Helicobacter pylori infection. Microbes Infect 19:449–458
Keenan J, Day T, Neal S et al (2000) A role for the bacterial outer membrane in the pathogenesis of Helicobacter pylori infection. FEMS Microbiol Lett 182:259–264
Olofsson A, Vallstrom A, Petzold K et al (2010) Biochemical and functional characterization of Helicobacter pylori vesicles. Mol Microbiol 77:1539–1555
Mullaney E, Brown PA, Smith SM et al (2009) Proteomic and functional characterization of the outer membrane vesicles from the gastric pathogen Helicobacter pylori. Proteomics Clin Appl 3:785–796
Grubman A, Kaparakis M, Viala J et al (2010) The innate immune molecule, NOD1, regulates direct killing of Helicobacter pylori by antimicrobial peptides. Cell Microbiol 12:626–639
Rad R, Ballhorn W, Voland P et al (2009) Extracellular and intracellular pattern recognition receptors cooperate in the recognition of Helicobacter pylori. Gastroenterology 136:2247–2257
Basu S, Pathak SK, Chatterjee G (2008) Helicobacter pylori protein HP0175 transactivates epidermal growth factor receptor through TLR4 in gastric epithelial cells. J Biol Chem 283:32,369–32,376
Mandell L, Moran AP, Cocchiarella A et al (2004) Intact gram-negative Helicobacter pylori, Helicobacter felis, and Helicobacter hepaticus bacteria activate innate immunity via toll-like receptor 2 but not toll-like receptor 4. Infect Immun 72:6446–6454
Torok AM, Bouton AH, Goldberg JB (2005) Helicobacter pylori induces interleukin-8 secretion by Toll-like receptor 2- and Toll-like receptor 5-dependent and -independent pathways. Infect Immun 73:1523–1531
Smith MF Jr, Mitchell A, Li G et al (2003) Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappa B activation and chemokine expression by epithelial cells. J Biol Chem 278:32,552–32,560
Pachathundikandi SK, Lind J, Tegtmeyer N et al (2015) Interplay of the gastric pathogen Helicobacter pylori with Toll-like receptors. Biomed Res Int 2015:192420
Pachathundikandi SK, Tegtmeyer N, Arnold IC et al (2019) T4SS-dependent TLR5 activation by Helicobacter pylori infection. Nat Commun 10:5717
Ding SZ, Torok AM, Smith MF Jr et al (2005) Toll-like receptor 2-mediated gene expression in epithelial cells during Helicobacter pylori infection. Helicobacter 10:193–204
Sayi A, Kohler E, Toller IM et al (2011) TLR-2-activated B cells suppress Helicobacter-induced preneoplastic gastric immunopathology by inducing T regulatory-1 cells. J Immunol 186:878–890
Pachathundikandi SK, Brandt S, Madassery J et al (2011) Induction of TLR-2 and TLR-5 expression by Helicobacter pylori switches cagPAI-dependent signalling leading to the secretion of IL-8 and TNF-alpha. PLoS One 6:e19614
Kim DJ, Park JH, Franchi L et al (2013) The Cag pathogenicity island and interaction between TLR2/NOD2 and NLRP3 regulate IL-1beta production in Helicobacter pylori infected dendritic cells. Eur J Immunol 43:2650–2658
Koch KN, Muller A (2015) Helicobacter pylori activates the TLR2/NLRP3/caspase-1/IL-18 axis to induce regulatory T-cells, establish persistent infection and promote tolerance to allergens. Gut Microbes 6:382–387
Koch KN, Hartung ML, Urban S et al (2015) Helicobacter urease-induced activation of the TLR2/NLRP3/IL-18 axis protects against asthma. J Clin Invest 125:3297–3302
Smith SM, Freeley M, Moynagh PN et al (2016, 2017) Differential modulation of Helicobacter pylori lipopolysaccharide-mediated TLR2 signaling by individual Pellino proteins. Helicobacter 22. https://doi.org/10.1111/hel.12325
Neuper T, Frauenlob T, Sarajlic M et al (2020) TLR2, TLR4 and TLR10 shape the cytokine and chemokine release of H. pylori-infected human DCs. Int J Mol Sci 21:3897
Takenaka R, Yokota K, Ayada K et al (2004) Helicobacter pylori heat-shock protein 60 induces inflammatory responses through the Toll-like receptor-triggered pathway in cultured human gastric epithelial cells. Microbiology 150(Pt 12):3913–3922
Zhao Y, Yokota K, Ayada K et al (2007) Helicobacter pylori heat-shock protein 60 induces interleukin-8 via a Toll-like receptor (TLR)2 and mitogen-activated protein (MAP) kinase pathway in human monocytes. J Med Microbiol 56:154–164
Amedei A, Cappon A, Codolo G et al (2006) The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest 116:1092–1101
McClain MS, Voss BJ, Cover TL (2020) Lipoprotein processing and sorting in Helicobacter pylori. mBio 11:e00911–e00920
Melit LE, Marginean CO, Marginean CD et al (2019) The relationship between Toll-like receptors and Helicobacter pylori-related gastropathies: still a controversial topic. J Immunol Res 2019:8197048
Chochi K, Ichikura T, Kinoshita M et al (2008) Helicobacter pylori augments growth of gastric cancers via the lipopolysaccharide-toll-like receptor 4 pathway whereas its lipopolysaccharide attenuates antitumor activities of human mononuclear cells. Clin Cancer 14:2909–2917
Ishihara S, Rumi MA, Kadowaki Y et al (2004) Essential role of MD-2 in TLR4-dependent signaling during Helicobacter pylori-associated gastritis. J Immunol 173:1406–1416
Kawahara T, Teshima S, Oka A et al (2001) Type I Helicobacter pylori lipopolysaccharide stimulates toll-like receptor 4 and activates mitogen oxidase 1 in gastric pit cells. Infect Immun 69:4382–4389
Cullen TW, Giles DK, Wolf LN et al (2011) Helicobacter pylori versus the host: remodeling of the bacterial outer membrane is required for survival in the gastric mucosa. PLoS Pathog 7:e1002454
Su B, Ceponis PJ, Lebel S et al (2003) Helicobacter pylori activates Toll-like receptor 4 expression in gastrointestinal epithelial cells. Infect Immun 71:3496–3502
Lepper PM, Triantafilou M, Schumann C et al (2005) Lipopolysaccharides from Helicobacter pylori can act as antagonists for Toll-like receptor 4. Cell Microbiol 7:519–528
Triantafilou M, Gamper FG, Lepper PM et al (2007) Lipopolysaccharides from atherosclerosis-associated bacteria antagonize TLR4, induce formation of TLR2/1/CD36 complexes in lipid rafts and trigger TLR2-induced inflammatory responses in human vascular endothelial cells. Cell Microbiol 9:2030–2039
Yokota S, Ohnishi T, Muroi M et al (2007) Highly-purified Helicobacter pylori LPS preparations induce weak inflammatory reactions and utilize Toll-like receptor 2 complex but not Toll-like receptor 4 complex. FEMS Immunol Med Microbiol 51:140–148
Nagashima H, Iwatani S, Cruz M et al (2015) Toll-like receptor 10 in Helicobacter pylori infection. J Infect Dis 212:1666–1676
Stein SC, Faber E, Bats SH et al (2017) Helicobacter pylori modulates host cell responses by CagT4SS-dependent translocation of an intermediate metabolite of LPS inner core heptose biosynthesis. PLoS Pathog 13:e1006514
Zimmermann S, Pfannkuch L, Al-Zeer MA et al (2017) ALPK1- and TIFA-dependent innate immune response triggered by the Helicobacter pylori type IV secretion system. Cell Rep 20:2384–2395
Gall A, Gaudet RG, Gray-Owen SD et al (2017) TIFA signaling in gastric epithelial cells initiates the cag type 4 secretion system-dependent innate immune response to Helicobacter pylori infection. mBio 8:e01168–e01117
Karkhah A, Ebrahimpour S, Rostamtabar M et al (2019) Helicobacter pylori evasion strategies of the host innate and adaptive immune responses to survive and develop gastrointestinal diseases. Microbiol Res 218:49–57
Bagheri N, Salimzadeh L, Shirzad H (2018) The role of T helper 1-cell response in Helicobacter pylori-infection. Microb Pathog 123:1–8
Zheng PY, Jones NL (2003) Helicobacter pylori strains expressing the vacuolating cytotoxin interrupt phagosome maturation in macrophages by recruiting and retaining TACO (coronin 1) protein. Cell Microbiol 5:25–40
Gebert B, Fischer W, Weiss E et al (2003) Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science 301:1099–1102
Mirzaei N, Poursina F, Moghim S et al (2017) The study of H. pylori putative candidate factors for single-and multi-component vaccine development. Crit Rev Microbiol 43:631–650
Lehours P, Ferrero RL (2019) Review: Helicobacter: inflammation, immunology, and vaccines. Helicobacter 24:e12644
Guo L, Yang H, Tang F et al (2017) Oral immunization with a multivalent epitope-based vaccine, based on NAP, urease, HSP60, and HpaA, provides therapeutic effect on H. pylori infection in mongolian gerbils. Front Cell Infect Microbiol 7:349
Zeng M, Mao X-H, Li J-X et al (2015) Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386:1457–1464
Acknowledgments
Support is acknowledged from the Health Research Board and a Trinity College Dublin Provost PhD Award.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
FitzGerald, R., Smith, S.M. (2021). An Overview of Helicobacter pylori Infection. In: Smith, S.M. (eds) Helicobacter Pylori. Methods in Molecular Biology, vol 2283. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1302-3_1
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1302-3_1
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1301-6
Online ISBN: 978-1-0716-1302-3
eBook Packages: Springer Protocols